Company
Headquarters: Taipei, Taiwan
CEO: Mr. Hong-Ren Wang Ph.D.
TW$10.19 Billion
TWD as of Jan. 1, 2026
US$325.2 Million
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
PharmaEngine, Inc., a biopharmaceutical company, engages in the development and licensing of drugs and therapeutic drugs for treating cancer diseases in Taiwan and Europe. It is developing ONIVYDE for patients with gemcitabine-treated metastatic pancreatic cancer;PEP06, which is in Phase I stage for the treatment of cancer; and PEP07, an oral small molecule drug, which is in preclinical development stage to regulate DNA damage response. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.
PharmaEngine, Inc. has the following listings and related stock indices.
Stock: TWSE: 4162